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Abstract: The interferon-gamma release assay (IGRA) is used to diagnose cases of feline mycobac-
teriosis, but the use of serial testing to monitor treatment responses has not been evaluated in this
species. From a population of cats that underwent IGRA testing for diagnostic investigation, in-
dividuals were identified with a pre- and end-of-treatment IGRA that passed control thresholds.
The number of cats which reverted to negative at the end-of-treatment IGRA, changes in paired
antigen-specific optical density (OD) values and differences in the pre-treatment antigen-specific
OD values for those which underwent reversion were compared. Factors to explain reversion or
recurrence of disease post-treatment were explored. Four of 18 cats (22%) reverted to negativity at
the point of clinical resolution (p = 0.33), there was no difference in paired antigen-specific OD values
(p ≥ 0.12), and cats that reverted did not have a lower baseline OD value (p = 0.63). No statistically
significant factors were identified to predict reversion (p ≥ 0.08). Remaining positive at the end of
treatment IGRA was not associated with recurrence of disease post-treatment (p = 0.34). Overall,
these data suggest there is limited value in the use of the IGRA to monitor treatment responses
in cats.
Keywords: cat; tuberculosis; mycobacteria; monitoring; interferon-gamma release assay; diagnostics
1. Introduction
Mycobacteriosis is a substantial issue within the domestic cat population in Great
Britain, with an estimated 1% of all routine feline biopsy submissions showing changes
suggestive of mycobacterial disease [1]; however, many cases may not initially be recog-
nised by practitioners. There are many challenges when faced with a suspected case of
mycobacterial disease, notably obtaining an accurate diagnosis, monitoring the response
to therapy, and identifying when treatment with antimicrobials can be stopped. Current
options for diagnosing mycobacterial infections in cats are limited to specialist mycobacte-
rial culture, molecular-based methods, i.e., polymerase chain reaction (PCR) and genome
sequencing, or the interferon-gamma (IFNγ) release assay (IGRA) [2].
Initially established for diagnosing tuberculosis (TB) in cattle where tuberculin skin
testing failed to identify all infected animals [3], the IGRA has since been adapted for
the diagnosis of TB in other species [4,5], including cats [6]. These assays detect the
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cellular immune response through secretion of IFNγ by T-cells following stimulation with
mycobacterial antigens [7]. The feline IGRA is designed to detect and discriminate between
infection with the two most common causes of mycobacteriosis in this species in Great
Britain, i.e., Mycobacterium (M.) microti and M. bovis [8], which both cause TB. The IGRA
also has some capacity to detect infections with M. avium and other non-tuberculous
mycobacteria [9]. While the IGRA appears useful for diagnosing mycobacteriosis in cats,
its clinical utility for monitoring the response to treatment in this species is unknown.
The IGRA is an immunological test based on sensitised antigen-specific T-cells re-
sponding to repeated antigenic stimulation in vitro [7], and its methodologies and use
in people have been thoroughly evaluated [10]. It is thought that the number of IFNγ-
secreting effector T-cells is proportional to the antigenic load, which is taken to reflect
the bacterial load [11,12], and that successful antimycobacterial treatment will result in a
decrease of this antigenic stimulus and a subsequent reduction in the number of antigenic-
specific effector T-cells [13]. Therefore, it has been proposed that serial IGRA testing for
those receiving antimycobacterial chemotherapy may be of some benefit [14]. Early investi-
gations of serial IFNγ responses showed that region of difference-1 (RD-1) markers, such
as early secreted antigenic target 6kDa (ESAT-6), were more likely to decrease in those with
a good response to treatment than responses to the crude purified protein derivative (PPD)
antigen [15], and human IGRA tests have since been designed using RD-1 antigens. Despite
this, in people, reversion from IGRA positivity at the time of diagnosis to negativity at the
conclusion of therapy has been shown to range from as low as 5.5% [16] up to 71% [17].
However, remaining positive at the end of treatment IGRA is not always associated with
an unfavourable outcome [16,18]. While changes in the categorical classification of IGRA
results has not been suggested as helpful for assessing successful response to therapy, the
magnitude of change in the IFNγ response may be of more benefit, as a small majority
of studies has shown a significant decrease in this measure between the start and end
of treatment [19]. Despite this, some studies have shown no change between pre- and
post-treatment IFNγ levels [20,21], while others have shown an increase [18]. There are
limitations to some of the methodologies of these studies making it difficult to accurately
compare and collate findings, namely, variable sample sizes, genetic differences across
populations studied, the level of TB exposure across different populations, co-morbidities,
and the censoring of data exceeding the upper limit of quantification. A systematic review
of 30 studies using serial IGRA testing to monitor the response to anti-TB chemotherapy
failed to show a consensus in the rate of reversion with highly variable results between
patients within studies, as well as rates across studies. Therefore, repeat IGRA testing is
not recommended to monitor individual patient responses to treatment in humans [19].
Serial IGRA testing has been previously reported in a small number of cats treated for
confirmed or suspected mycobacteriosis [9,22], most of whom remained positive despite
apparent resolution of disease. However, it is unknown whether these findings are repre-
sentative of the IFNγ response in a larger population of cats or whether we should aim for
reversion to IGRA negativity when treating cases of feline mycobacterial disease.
The objective of this study was to determine whether serial IGRA tests are of benefit
for monitoring the response to antimycobacterial therapy in cats. We assessed whether
reversion to IGRA negativity was observed in association with apparent clinical resolution.
We also measured the change in the magnitude of the IFNγ response and investigated
factors that might influence reversion to IGRA negativity or the risk of recurrence of
mycobacterial disease post-treatment.
2. Results
2.1. Study Population Selection and Summary Statistics
The selection process to identify eligible cats that underwent serial IGRA testing while
receiving antimycobacterial treatment is shown in Figure 1. In total, 741 IGRAs were
performed on 594 individual cats, with 107 cats having had more than one test. Fifty-one
cats had at least two tests which passed the test criteria (see 4.1. Study Population Selection).
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Of the 56 cats that did not pass these criteria: 49 were excluded as they did not meet
the conditions for a passing optical density (OD) positive control (PC) and/or positive
control–negative control (NC) OD values, four had coefficient of variation (CV) values
exceeding 30% for at least one test condition (including six that also did not meet the
ODPC/ODPC-ODNC thresholds), and three had average ODNC values greater than 0.30.
Active mycobacterial disease was diagnosed in 36 of the 51 cats with at least two tests
meeting the IGRA inclusion criteria, and of these 18 were included for final analysis as
they did not have a previous history of being treated for mycobacterial disease. Both tests
passed quality control (QC) thresholds and they were conducted (pre-treatment and at the
end of treatment) within the same episode of active clinical disease.
Figure 1. Flow diagram to show the decision-making process for identifying cats assessed by serial interferon-gamma release
assay (IGRA) for subsequent analysis. IGRA = interferon-gamma release assay; Passing = optical density (OD) positive
control (PC) ≥ 0.40, OD negative control (NC) ≤ 0.30, and ODPC-ODNC ≥ 0.10, or if ODPC < 0.40, ODPC-ODNC ≥ 0.20.
Coefficient of variation between duplicate PC and NC wells ≤ 30%.
Clinical data for the cats in this study are summarised in Table 1. The median age of
cats at the time of the pre-treatment IGRA was 6.75 years (0.5–13 years), and 15 (83%) were
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neutered males. Twelve cats (67%) were domestic short-hair (DSH); the remaining breeds
were Siamese (n = 4), Bengal (n = 1), and Tonkinese (n = 1). Three cats were diagnosed with
M. bovis by culture, one cat was culture- and PCR-positive for M. microti, and three further
cats were diagnosed with M. tuberculosis-complex (MTBC) infection on PCR [23], but there
was insufficient DNA to define the infectious agent further. Two cats were negative for
Mycobacterium species on culture, and another cat was culture- and PCR-negative. The
remaining eight cats did not undergo culture or PCR testing. Lymphadenopathy was
identified in 13 cats (72%), including one cat with tonsillar lymphoid hyperplasia, followed
by cutaneous lesions in seven (39%) and ocular lesions in three (17%). Twelve cats (67%)
had an abnormal pulmonic lung pattern on radiography or computed tomography (CT).
Testing for feline leukaemia virus antigen and feline immunodeficiency virus antibody was
performed in five cats and all were negative. Hypercalcaemia was identified in four of nine
cats tested (44%); one cat had increased total calcium, but ionised calcium was within the
reference interval, another cat with increased total calcium did not have ionised calcium
measured, and the remaining two cats both had increased ionised calcium.
Therapeutic interventions varied. The median duration of antimycobacterial treatment
was six months (range 3–24 months). Ten cats (56%) were maintained on ‘triple therapy’
with rifampicin, azithromycin, or clarithromycin, and pradofloxacin for the entire duration
of their treatment protocol; two of these cats also underwent surgery (i.e., enucleation)
prior to medical management. Four cats (22%) were started on ‘triple therapy’, with dis-
continuation of rifampicin after two and six months in two cats, whereas azithromycin was
discontinued in two cats after two and three months. Azithromycin or clarithromycin were
substituted for erythromycin in one cat, in conjunction with rifampicin and pradofloxacin.
One cat was treated with rifampicin, azithromycin, and marbofloxacin, with discontin-
uation of rifampicin after three months. A protocol of rifampicin, pradofloxacin, and
clindamycin was started in one cat with suspected concurrent toxoplasmosis; clindamycin
was then replaced with azithromycin after three months. The final cat was treated with a
combination of erythromycin, doxycycline, and pradofloxacin.
Recurrence of clinical signs attributable to mycobacteriosis following resolution of
disease was identified in five cases, all of which had radiographic evidence of pulmonic
disease. The median duration to the onset of recurrent clinical signs was 16 months
(3–27 months). Two of these cats were subsequently euthanased, whereas treatment was
re-instated for the other three cats; clinical resolution was achieved in two of these cats,
while the third was lost to follow-up.
2.2. Qualitative Classification of IGRA Results
Pre- and end-of-treatment IGRA results were interpreted according to the pattern of
responses to each antigen and scored on a positive–negative basis (Table 2). All 18 cats
were positive on the pre-treatment IGRA, showing a biased response to PPD from M.
bovis (PPDB), suggesting infection with a member of the MTBC. Three cases were positive
to early secreted antigenic target 6kDa-culture filtrate protein 10kDa (ESAT-6/CFP-10
[E6C10]); two were culture-positive for M. bovis (cases 9 and 11). One cat (case 2) had a
culture-confirmed diagnosis of M. bovis infection, but was negative to E6C10 on IGRA. At
the end-of-treatment IGRA, 14 (78%) were persistently positive and four (22%) underwent
reversion to negativity. A PPDB-biased response was maintained in all 14 persistently
positive cats. In addition to the two E6C10-positive cats with culture-confirmed M. bovis
infection on the initial IGRA, two further cats were now positive to E6C10 at the end-
of-treatment IGRA. Neither of these cats were case 2, the M. bovis culture-positive cat,
which remained negative to E6C10. The proportion of cats that reverted to a negative
end-of-treatment IGRA was not statistically different to that seen in humans treated for
active TB (p = 0.33), i.e., the rates of reversion are similar.
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Table 1. Summary of the details of the cats included in this study.














2 3 FN Siamese M. bovis b NP NP
Lip mass, submandibular
lymphadenopathy,
bronchointerstitial lung pattern c
R/A/P (6) Resolved (18)
3 0.5 MN DSH MTBC a NP Normal (total) Interstitial lung pattern c R/A/P (3); R/P(15) Resolved (3)





lymphadenopathy R/A/P (6) Resolved (48)
5 7 MN Siamese M. microti a,b Negative Normal (total)
Multiple cutaneous masses,
bronchointerstitial lung pattern c
R/A/P (2); R/P
(6) Resolved (12)
6 7 MN DSH NP NP NP
Bilateral submandibular
lymphadenopathy,





months later; retreated with
R/A/P, lost to follow-up






Re-presented with mass on
lip 17 months later;
retreated with R/A/P for
four months, resolved
8 11 MN Siamese NP Negative Increased(ionised)
Tonsillar lymphoid hyperplasia,
alveolar lung pattern c
R/A/M (3);
A/M (12) Resolved (12)
9 7 MN DSH M. bovis b NP NP Conjunctival mass
R/A/P (3); A/P
(2) Resolved (6)
10 6.5 FN DSH Negative b NP NP
Multiple cutaneous masses,
peripheral lymphadenopathy
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Table 1. Cont.








11 5 MN DSH M. bovis b NP Normal (total)
Discharging cutaneous mass,
perihilar lymphadenopathy,
interstitial lung pattern c
R/A/P (6); A/P
(18) Resolved (42)
12 13 MN Bengal NP NP Normal (total) Generalised lymphadenopathy,bronchointerstitial lung pattern d R/A/P (9)
Recurrence of clinical signs
three months later;
euthanased
13 5.5 MN DSH Negative b NP NP
Generalised lymphadenopathy,
bronchointerstitial lung pattern c R/A/P (6) Resolved (6)





R/A/P (3) Resolved (36)
15 3 FN DSH NP NP NP Submandibularlymphadenopathy E/D/P (6) Resolved (6)
16 1.5 MN Tonkinese NP Negative Increased (total,ionised) Diffuse interstitial lung pattern
c R/Ct/P (8)
Recurrence of clinical signs
16 months later; retreated
with R/Ct/P for eight
months, resolved
17 8.5 MN DSH NP NP Normal (total) Generalised lymphadenopathy R/E/P (4) Resolved (24)





FeLV Ag = feline leukaemia virus antigen. FIV Ab = feline immunodeficiency virus antibody. MN = male neutered. FN = female neutered. DSH = domestic short-hair. MTBC = Mycobacterium tuberculosis-complex.
NP = not performed. R = rifampicin. A = azithromycin. P = pradofloxacin. M = marbofloxacin. E = erythromycin. D = doxycycline. Ct = clarithromycin. Cd = clindamycin. a = PCR diagnosis. b = culture
diagnosis. c = thoracic radiography. d = computed tomography.
Pathogens 2021, 10, 657 7 of 15
Table 2. Binary classification and interpretation of interferon-gamma release assay (IGRA) results prior to starting antimy-
cobacterial therapy and at the point of treatment cessation, and categorisation of the pattern. Positivity was ascribed to
an IGRA with a positive result to any test antigen, whereas a negative result indicated an optical density value below
positivity-thresholds for all test antigens.
Case Pre-Treatment IGRA IGRA Result End-of-Treatment IGRA IGRA Result Pattern
1 Positive B > A Positive B > A Persistent positive
2 Positive B > A Positive B > A Persistent positive
3 Positive B > A Positive B > A, E positive Persistent positive
4 Positive B > A Positive B > A Persistent positive
5 Positive B > A Positive B > A Persistent positive
6 Positive B > A Positive B > A Persistent positive
7 Positive B > A Positive B > A Persistent positive
8 Positive B > A Positive B > A, E positive Persistent positive
9 Positive B > A, E positive Positive B > A, E positive Persistent positive
10 Positive B > A Positive B > A Persistent positive
11 Positive B > A, E positive Positive B > A, E positive Persistent positive
12 Positive B > A Positive B > A Persistent positive
13 Positive B > A Positive B > A Persistent positive
14 Positive B > A Positive B > A Persistent positive
15 Positive B > A Negative Negative Reversion
16 Positive B > A Negative Negative Reversion
17 Positive B > A Negative Negative Reversion
18 Positive B > A, E positive Negative Negative Reversion
Tuberculin-bias is indicated by >. B = purified protein derivative (PPD) from M. bovis (PPDB). A = PPD from M. avium (PPDA). E = early
secreted antigenic target 6kDa/culture filtrate protein 10kDa (ESAT6/CFP10).
2.3. Quantitative Evaluation of IGRA Responses
To account for intra-cat variability between IGRA results that passed QC thresholds,
paired ODPC values for each cat at pre- and end-of-treatment IGRA were compared to
identify overlap in these values, allowing for comparison of antigen OD values. Eleven
of the 18 cats had overlapping ODPC values between the pre- and end-of-treatment IGRA
(data not shown).
Of these 11 cats, eight (73%) showed a decrease in the ODPPDB value between the pre-
and end-of-treatment IGRA (Figure 2A). There was a decrease in the ODE6C10 value in three
of the five cats that were culture- or IGRA-positive for infection with M. bovis (Figure 2B).
The median OD values for both PPDB and E6C10 decreased (0.49 to 0.22 ODPPDB; 0.15
to 0.06 ODE6C10), but there was no statistically significant difference between paired OD
values for either antigen (ODPPDB, p = 0.12; ODE6C10, p = 0.81).
The pre-treatment ODPPDB values were compared between cats that were persistently
positive at the end-of-treatment IGRA (n = 8) and those that reverted to negative (n = 3)
(Figure 3). The median ODPPDB value was higher in the persistently positive group (0.58)
compared to the reversion group (0.38), however this difference was not statistically
significant (p = 0.63).
2.4. Logistic Regression Analysis
Logistic regression was performed to identify potential factors that may predict re-
version to IGRA negativity at the end-of-treatment IGRA or recurrence of disease. For
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reversion, a multivariate model with age, gender, breed (DSH vs non-DSH), the presence or
absence of pulmonic disease, and treatment regimen (‘triple therapy’ as at least part of the
treatment protocol for at least three months in cases without pulmonic disease and at least
six months in cases with pulmonic disease vs ‘triple therapy’ as at least part of the treatment
protocol for an insufficient duration of time as well as all other protocols) was constructed.
The multivariate model then underwent stepwise multidirectional reduction to its simplest
components. Exploration of the full multivariate model revealed high collinearity between
non-DSH cats and the presence of pulmonic disease, with no statistically significant factors
for IGRA reversion identified. The reduced model identified younger age and the absence
of pulmonic disease as the most important factors in predicting reversion to IGRA nega-
tivity at the end of treatment, but neither were statistically significant (age, p = 0.08, odds
ratio [OR] = 0.50 [0.23−1.09]; pulmonic disease, p = 0.17, OR = 0.05 [0.0006–3.88]).
Figure 2. Paired average negative control corrected-OD values for pre- and end-of-treatment IGRA
for (a) PPDB (n = 11) and (b) E6C10 (n = 5). The dotted line at OD 0.07 signifies the threshold for
PPDB positivity. The dotted line at OD 0.05 signifies the threshold for E6C10 positivity. OD = optical
density. IGRA = interferon-gamma release assay. PPDB = purified protein derivative from M. bovis.
E6C10 = ESAT-6/CFP-10 antigenic cocktail.
Figure 3. Pre-treatment IGRA average ODPPDB values for cats who remained positive at the end-of-
treatment IGRA (n = 8) compared to those which reverted to negative (n = 3). The solid line shows
the median OD value for each group. The dotted line at OD 0.07 signifies the threshold for PPDB
positivity. OD = optical density. IGRA = interferon-gamma release assay. PPDB = purified protein
derivative from M. bovis.
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Factors included in the multivariate model for the risk of disease recurrence included
those modelled for reversion, in addition to remaining persistently positive at the end-
of-treatment IGRA. There was no statistically significant association between remaining
persistently positive at the end-of-treatment IGRA and recurrence of disease (p = 0.34,
OR = 0.06 [0.0002–19.26]). Quasi-complete separation of the data was identified; radio-
graphic evidence of pulmonic disease at the initial presentation was recorded in all five
cats that had recurrence of clinical signs attributable to mycobacterial disease, compared to
seven cats (54%) that did not redevelop clinical signs of mycobacteriosis. Pulmonic disease
was the only factor remaining in the model following multidirectional stepwise reduction.
3. Discussion
This study investigated serial IGRA testing in cats with active mycobacterial disease
and whether it can be used to monitor the response to antimycobacterial treatment. Four-
teen out of 18 (78%) cats were persistently positive across the pre- and end-of-treatment
IGRA, despite apparent clinical resolution of disease. Where comparable, paired OD val-
ues for PPDB and E6C10 antigen responses showed no statistically significant difference
between the pre- and end-of-treatment IGRA, although the median OD value for both
antigens was slightly lower at the end-of-treatment IGRA compared to the pre-treatment
results. There was also no statistically significant difference between the pre-treatment
ODPPDB value for cats that remained persistently positive to those that reverted to negative
at the end-of-treatment IGRA. No statistically significant factors were identified to predict
reversion to negativity at the end-of-treatment IGRA, and there was no association between
the end-of-treatment IGRA result and recurrence of disease post-treatment. However, all
five cats that had recurrence of clinical signs attributable to mycobacteriosis had evidence
of pulmonic disease as part of their initial diagnostic investigation, compared to similar
changes being identified in only seven of 13 cats (54%) that did not have recurrence of
clinical signs during the available period of follow-up.
In line with previous studies on mycobacterial infections in Great Britain [8], most
cases reported here were neutered male cats. The most common breed was the DSH, which
reflects the domestic cat population in Great Britain, and the median age was nearly seven
years old, although disease was identified in cats as young as six months old. While only
seven cats presented with cutaneous lesions, 13 had a lymphadenopathy. Typically, cases
of feline mycobacterial disease present with cutaneous nodules, which may be ulcerating
and/or have discharging sinus tracts, with a secondary lymphadenopathy [8,24]. It may
be the case that small skin lesions were not identified in some of the cats in this study, or
subcutaneous masses closely associated with peripheral lymph nodes (i.e., submandibular
and popliteal lymph nodes) may have not been identified as unique entities, or these
cases presented at a later stage where lymph node changes were more prominent. An
abnormal radiographic lung pattern was present in two-thirds of the cats in this study
(12 of 18), with a bronchial/interstitial pattern most reported, which is in keeping with
previous studies [25,26]. This is putatively due to haematogenous spread of bacteria from
the primary site of infection, rather than inhalation of aerosolised mycobacteria which
would more likely result in cavitary lesions. Clinical resolution of disease with no evidence
of recurrence of clinical signs attributable to mycobacterial disease during the period of
follow-up for each individual cat was achieved in 13 cats (72%), which is substantially
higher than previously reported [27]. Other than one cat (case 15), all were treated with
a combination of rifampicin, a macrolide, or azalide, and a fluoroquinolone for at least
two months, although the choice of drugs and the duration varied greatly between cases.
While further investigation is required, this would suggest the use of some combination of
these drugs is suitable for treating cases of feline mycobacterial disease.
Other than in a small number of cases [9,22], the use of serial IGRA for monitoring the
response to antimycobacterial treatment in cats has not been investigated. The data from
the current study reflect observations from human studies of treating active mycobacterial
disease, in that reversion to IGRA negativity at the end of antimycobacterial therapy is
Pathogens 2021, 10, 657 10 of 15
uncommon [19]. Using feline-specific cut-off values to score IGRA antigen responses
(Mitchell et al., manuscript in preparation), all cases included in this study were positive
at the pre-treatment IGRA, and 78% of cases remained persistently positive at the end-of-
treatment IGRA despite apparent clinical resolution. This rate of persistent positivity is
similar to a pooled value of persistently positive humans following treatment for active
TB (p = 0.33); of 982 patients, 660 remained persistently positive (67%) [19]. It has been
suggested that maintenance of IGRA positivity could be due to improvement of the immune
response in individuals undergoing treatment [28] or an increase in the proportion of IFNγ-
secreting CD4+ T-cells [18]. It has also been recognised that clinically healthy individuals
previously treated for tuberculosis can retain specific effector memory T-cell responses long
after successful resolution of disease, although the precise mechanism driving this remains
unknown [29].
Quantitative classification of the IGRA response in animals is less straightforward than
in people, as these results are often reported as OD values [30,31]. Intra-subject variability
with repeat IGRA testing is recognised, further complicating the ability to accurately
compare serial IGRA results [28,32]. This variability can be problematic when interpreting
borderline test results, possibly accounting for reversions in the absence of treatment, or
conversions with no known exposure to Mycobacterium species [33]. In this study, a decrease
in the median OD value was observed between the pre- and end-of-treatment IGRA for
both PPDB and E6C10, although these differences were not statistically significant. Some
cats showed an increase in the OD value between tests, despite apparent clinical resolution;
this may be a result from continued expansion of T-cell subsets despite a decrease in the
antigenic load [11]. Other studies have shown a decrease in the response to RD-1 antigens
to be a better indicator of response to antimycobacterial therapy compared to PPD [15], but
this was not observed in this study. This could be due to the small number of cats infected
with mycobacteria that encode ESAT-6/CFP-10 in this study, and that approximately 20%
of cats infected with M. bovis may not produce a substantial IFNγ response to the E6C10
cocktail [9].
It has been suggested that IGRA reversion is more likely in humans with a lower
pre-treatment IFNγ concentration [13,34]; however, this observation is not consistent [17].
End-of-treatment IGRA reversion was identified in four cats in this study. While the
pre-treatment median ODPPDB value for cats that reverted (where comparable data was
available) was lower than those that remained positive, this difference was not statistically
significant. This is probably influenced by the small study population. Logistic regression
did not identify any factors associated with reversion to IGRA negativity; although not
significant (p = 0.08), this study did show a slight trend with a decrease in the odds of
reverting to a negative end-of-treatment IGRA with an increase in age (OR 0.50 [0.23–1.09]).
This is similar to studies in humans, where older individuals were more likely to remain
positive at the end-of-treatment IGRA despite resolution of disease [35]. One feature
of ageing in humans is an increase in the number of memory T-cells; however, chronic
antigenic stimulation can also result in the development of an oligoclonal population
with impaired function [36]. While there are few studies describing changes in the feline
immune system with age, it has been shown that older cats have reduced numbers of
many cell populations, including CD4+ T-cells and CD56+ Natural Killer cells, as well as a
reduction in the CD4:CD8 ratio [37,38]. Changes in immune cell populations and function
with age may be reflected with this decrease in the odds of IGRA reversion with age.
In the current study, recurrence of disease was not associated with a persistently
positive pattern of IGRA results, albeit the number of cats with recurrence of disease
was low so the results should be interpreted cautiously. All cats who re-presented with
clinical signs suggestive of mycobacterial disease had evidence of pulmonic disease on
thoracic imaging when they initially presented. This may reflect a reduced capacity
for the host immune system to restrict the spread of mycobacteria from the primary
site of infection, or differences in the virulence of different species and/or strains of
mycobacteria. Consequently, once treatment has been stopped on the basis of the cat
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achieving clinical resolution, any mycobacteria that may have been dormant or hidden
from the immune system could reactivate, resulting in the recurrence of clinical signs
associated with mycobacteriosis. Previous studies have shown that while both radiography
and CT are of benefit in the investigation of cases of feline mycobacteriosis [25,26], CT is
more sensitive at detecting pulmonic changes attributed to mycobacterial infection, and
that post-treatment small lesions may be missed with conventional radiography [22]. In
the current study, most cats underwent radiography rather than CT, which may have not
identified small regions of lung pathology at the end of treatment, resulting in treatment
being withdrawn early and subsequent relapse. Data from cattle experimentally infected
with M. bovis and treated with isoniazid showed an increase in the IFNγ response to
stimulation with ESAT-6/CFP-10 after treatment was stopped, most notably in cattle with
visible lesions at post-mortem examination, indicating incomplete treatment and failure
to eliminate all mycobacteria [39]. One complicating factor is the dynamics of feline
mycobacterial infections; although four of the five cats re-presented with clinical signs
identical to their initial presentation, this could be due to reinfection from environmental
sources, i.e., hunting prey, or true recrudescence of disease. Further analysis of treatment
outcomes in cases of mycobacterial disease is needed. Altogether, these results suggest that
attaining IGRA negativity in cats treated for mycobacterial disease is unlikely, and it does
not imply any benefit regarding long-term outcomes.
There are limitations to this study, most notably the small sample size. While there
were 594 individual cats that had been tested by IGRA, only 107 of these had more than
one IGRA performed, and of these only 18 met the final inclusion criteria. Cats with a
previous history of mycobacterial disease were excluded, as it has been shown in humans
that individuals with a history of TB later presenting with non-TB disease (including bron-
chopneumonia and lung neoplasia) can still generate a positive IGRA result that cannot be
distinguished from those with active TB [40]. Additionally, these were all naturally occur-
ring cases that were managed in practice by the referring veterinary surgeon (RVS), with
the authors overseeing case treatment remotely. Since the authors often became involved
after the initial treatment choices had been made, there was no standardised approach;
this was exacerbated by recent changes in treatment guidelines [2,41]. A prospective study
with a defined cohort of patients, tested at set time points, would provide stronger con-
clusions; however, the current study provides ‘real world’ representations of clinical data,
management of cases, and the limitations of test failures.
To conclude, serial IGRA testing to monitor the response to antimycobacterial chemotherapy
is of limited benefit in the cat; however, it may be warranted to perform an end-of-treatment
IGRA. Provided there is reversion to negativity, if the cat were to re-present with suspected
relapse or reinfection than an IGRA could be repeated, with a positive result suggesting
active mycobacterial disease. However, if the end-of-treatment IGRA were to remain posi-
tive, any further presentation with signs compatible with mycobacteriosis would require
demonstration of Ziehl–Neelsen (ZN)-positive organisms. If these cannot be identified,
alternative testing modalities, such as PCR or culture, would be advisable.
4. Materials and Methods
4.1. Study Population Selection
A retrospective analysis of IGRA results from cats tested for mycobacterial disease
by Biobest Laboratories, Scotland, between May 2013 and October 2019 was undertaken.
Each assay had been performed as previously described [9,31]. Test submission data and
results were cross-referenced with clinical data supplied by the RVS to the authors for case
advice and management. This was done in line with owner consent, and the RVS was
contacted for further clinical information when necessary. Individual cats with multiple
IGRA results were identified. The IGRA OD values, a correlate for the amount of IFNγ
secreted by T-lymphocytes in response to antigenic stimulation [30], were re-assessed in
accordance with current guidelines [42], which have subsequently been adapted for feline-
specific thresholds (Mitchell et al., manuscript in preparation). Briefly, for a test to pass
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QC thresholds, the mean ODPC had to be ≥ 0.40 and exceed the ODNC by at least 0.10 OD
units i.e., ODPC-ODNC ≥ 0.10; if the ODPC was < 0.40 it was considered a borderline pass
provided ODPC-ODNC ≥ 0.20. The ODNC also had to be ≤ 0.30. The CV for duplicate
control and test well OD values had to be within 30%. Individual cats without at least
two tests that had passed these criteria were excluded.
Supporting clinical data was consulted for each cat (where available) to identify those
with a final diagnosis of mycobacterial disease, either (1) confirmed with culture or PCR,
or (2) strongly suspected (i.e., supportive histopathology and/or ZN-positive staining of
tissue biopsy material, but no culture of PCR). Cats were excluded if they had insufficient
clinical records or had been tested as potential in-contact cases. Cats were also excluded if
they had been previously diagnosed and treated for an incidence of mycobacterial disease
prior to IGRA testing. To be included in this study, all cats had to have an IGRA performed
at the point of starting treatment for mycobacterial disease, and at the point of clinical
resolution of active disease when treatment was stopped.
4.2. Qualitative Interpretation of Results
For each cat that met the inclusion criteria described above, IGRA results were assessed
to identify a positive response to any of the test antigens. For antigen positivity, the
OD value for cells stimulated with PPD from M. avium (PPDA) and PPD from M. bovis
(PPDB) had to exceed the ODNC by 0.07, whereas the OD value for the antigenic cocktail
ESAT-6/CFP-10 had to exceed the ODNC by 0.05. A PPDA-biased response was given as
ODPPDA-ODPPDB ≥ 0.05, and a PPDB-biased response as ODPPDB-ODPPDA ≥ 0.05 [43]. A
test showing a positive response to any antigen was called positive, whereas a test lacking
a positive response to all antigens was called negative. Clinical records were consulted
to correlate the timing of IGRA tests with treatment. An IGRA was termed pre-treatment
if it was performed within two weeks of starting treatment for mycobacterial disease, or
before treatment had been instigated. The IGRA was deemed end-of-treatment if treatment
had been stopped within the proceeding two weeks, or if treatment was ceased within
four weeks of the test being performed. Once assigned as positive or negative, the pattern
of IGRA results was interpreted as follows: those that remained positive across both
tests were classified as persistently positive; those that changed from positive to negative
were classed as reversions. A one-sample chi-squared test was performed to determine if
the number of cats with a negative end-of-treatment IGRA differed from a hypothesised
proportion of reversion of 0.33 in humans with active TB [19]. Statistical significance was
set to p < 0.05, and data were analysed using RStudio Ver 1.2.1335 (RStudio, Inc., Boston,
MA, USA) [44].
4.3. Quantitative Interpretation of Results
Negative control-corrected paired ODPC values were compared across both testing
points for each cat by plotting the average ODPC value for each test with a 95% confidence
interval for the mean; tests with overlapping confidence intervals were considered compa-
rable. Wilcoxon signed-rank tests were performed to compare pre- and end-of-treatment
IGRA ODPPD and ODE6C10 values. The selection of either PPD antigen of ODPPD analysis
was based on demonstration of PPD-bias. Comparison of ODE6C10 values was undertaken
for cats who were IGRA-positive for this condition or were diagnosed by culture or PCR
with M. bovis, which encodes the genes for this antigenic cocktail (unlike M. microti). To
investigate whether cats who reverted from positive to negative at the end-of-treatment
IGRA had a lower pre-treatment ODPPD value compared to those who remained positive,
a Mann-Whitney U test was performed. Statistical significance was set to p < 0.05. Data
were analysed using RStudio Ver 1.2.1335, and graphs were created using GraphPad Prism
Ver 9.0.0 (GraphPad Software, San Diego, CA, USA).
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4.4. Identification of Factors Associated with IGRA Reversion and Recurrence of Disease
For cats with a valid pre- and end-of-treatment IGRA, logistic regression was per-
formed to identify predictors of reversion to negativity at the end-of-treatment IGRA, and
of disease recurrence after the cessation of antibiotic therapy. A multivariate model with all
potential explanatory factors was constructed for each outcome (reversion and recurrence).
A multidirectional stepwise approach was used to reduce the multivariate model to its
simplest components. Statistical significance in the reduced model was set to p < 0.05.
Logistic regression was performed using RStudio Ver 1.2.1335.
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